4-Chloro-7-fluoropyrrolo[1,2-a]quinoxaline, 95.0%, 250mg

Ethyl 2-(hydroxyimino)-3-oxobutanoate, 95.0%, 10g

(2E)-1-(3-bromophenyl)-3-(2,5-dimethoxyphenyl)prop-2-en-1-one, 95.0%, 2g

4-Bromo-5-(bromomethyl)-2-methylthiazole, 97.0%, 1g

1,4-Diazepan-2-one, 97.0%, 1g

3-Bromo-5-ethoxy-4-hydroxy-benzonitrile, 97.0%, 100mg

1-Aminonaphthalene, 95.0%, 25g

4-Bromo-N,N,2-trimethylbenzenesulfonamide, 97%, 5g

6,10-Dimethylundecan-2-one, 98%, 100mg

Microliter syringe GASTIGHT® series 1700 Point type 2, 500 µl, 1750 RN, 1 piece

2,4,5-Trichloropyrrolo[2,1-f][1,2,4]triazine, 98%, 100mg

8-Chloroimidazo[1,2-a]pyridine, 95.0%, 1g

4-CHLORO-6-METHYL-3-NITROPYRIDIN-2(1H)-ONE, 95.0%, 1g